Cairo - Mubasher: Hikma Pharmaceuticals, a global company with local presence in the US, the MENA region, and Europe, has penned a licensing and distribution agreement with Italy-headquartered Chiesi Farmaceutici, an international research-focused pharmaceutical group, to commercialise medical products in Egypt.

Under the agreement, Hikma will distribute eleven of Chiesi’s leading products, mainly respiratory and neonatal therapeutic products, in the Egyptian market. This agreement adds to the success of Hikma’s existing partnership with Cheisi in Morocco as well as its portfolio in Egypt.

Hikma’s executive vice chairman and president of MENA, Mazen Darwazah, said:“ In particular, this agreement enables us to meet the needs of a growing number of patients suffering from asthma and COPD in Egypt, and improve their access to high-quality medicines.”

Meanwhile, the CEO of Chiesi Group, Ugo Di Francesco, remarked: “This will allow us to increase the availability of our main therapeutic solutions in the respiratory and neonatology fields to Egyptian patients.”